Abstract 4227
Background
Tumor-associated macrophages (TAMs) are a major component of innate immunity supporting primary tumor growth and metastasis. Chemotherapy is one of the main treatment strategies for solid tumors, while chemoresistance is the major limitation of the chemotherapy for patients with various types of cancer. A number of evidence indicate that TAMs can accumulate in tumors after chemotherapy and contribute to chemoresistance.
Methods
For the endocytic uptake of EGF we used flow cytometry analysis. Confocal microscopy was used for the analysis of stabilin-1-mediated internalization and endocytic trafficking of EGF in CHO cells and in modeled TAMs differentiated in the presence of conditioned supernatants of breast cancer (MCF-7) and colorectal cancer (Colo206F) cell lines. We performed next-generation sequencing of RNA samples obtained from our modeled TAMs. Validation of sequencing data by real-time PCR was performed for selected genes implicated in the endocytic uptake: DNM3, STX8, DENND1A and EHD1.
Results
For the first time we demonstrated that stabilin-1 ectopically expressed in CHO cells mediates endocytic uptake of EGF, key growth factor stimulating progression of breast and colorectal cancer. In the model of primary human TAMs, we have demonstrated that cisplatin decreases stabilin-1-mediated internalization and endocytic trafficking of EGF, without affecting gene expression of scavenger receptor stabilin-1. Molecular mechanisms of cisplatin effect on TAMs were uncovered using high throughput RNA sequencing. Gene set enrichment analysis identified that cisplatin contributes to defects in endocyting machinery reducing membrane biogenesis and vesicular transport. Significant suppression of DNM3, STX8, DENND1A and EHD1 genes expression by cisplatin was confirmed by RT-PCR.
Conclusions
We suggested that suppression of receptor-mediated clearance of tumor-supportive factors, such as EGF, by chemotherapeutic drugs may potentially lead to the tumor progression and/or relapse as a mechanism of macrophage-mediated chemoresistance. This study was supported by grand RSF №19-15-00151.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Research Tomsk State University.
Funding
RSF N19-15-00151.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
920 - Efficacy of intravenous (IV) NEPA, a fixed NK1/5-HT3 receptor antagonist (RA) combination, for prevention of CINV following cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy (CT)
Presenter: Lee Schwartzberg
Session: Poster Display session 1
Resources:
Abstract
5146 - Efficacy of olanzapine combination in prevention of nausea & vomiting in highly emetogenic chemotherapy
Presenter: Smitha Saldanha
Session: Poster Display session 1
Resources:
Abstract
1947 - Patient-reported outcome data during real-world use of NEPA for prevention of chemotherapy-induced nausea and vomiting in high-risk platin-receiving patients - A prospective multicenter trial
Presenter: Meinolf Karthaus
Session: Poster Display session 1
Resources:
Abstract
6163 - A study evaluating steroid induced metabolic syndrome after antiemetic dexamethasone therapy in patients received high emetic risk chemotherapy
Presenter: Hee Jun Kim
Session: Poster Display session 1
Resources:
Abstract
2154 - High incidence of nausea during initial and repeated courses if intravenous chemotherapy in patients receiving guideline consistent antiemetic prophylaxis - a prospective, observational, real world study.
Presenter: Teresa Smit
Session: Poster Display session 1
Resources:
Abstract
1637 - "Randomised controlled trial of Scalp Cooling (SC) for the prevention of Chemotherapy Induced Alopecia (CIA)”
Presenter: Jyoti Bajpai
Session: Poster Display session 1
Resources:
Abstract
5351 - Performance of the ‘4S rule’ to predict short-term outcomes in cancer outpatients with unsuspected pulmonary embolism.
Presenter: David Pesántez Coronel
Session: Poster Display session 1
Resources:
Abstract
1189 - Prevalence of venous thromboembolism based on intensive screening for patients with advanced solid tumor in prospective observational study
Presenter: Shota Omori
Session: Poster Display session 1
Resources:
Abstract
4340 - Short-term outcomes of cancer patients with pulmonary embolism according to the setting (hospital-acquired vs. outpatient) at diagnosis.
Presenter: Diego Muñoz Guglielmetti
Session: Poster Display session 1
Resources:
Abstract
4658 - Patient-reported outcomes associated with switching to rivaroxaban for the treatment of venous thromboembolism (VTE) in patients with active cancer
Presenter: Alexander Cohen
Session: Poster Display session 1
Resources:
Abstract